[ORGANIZATION]
Auryxia
Featured in 1 tracked story · first seen
Situations
Akebia Therapeutics Q2 financial and clinical results
2 clusters · 4 sources · last updated
Latest: Axsome Therapeutics reports 46% revenue growth in Q2 2026
Akebia Therapeutics reported second-quarter results characterized by a significant divergence in product performance. Revenue for its anemia drug, Vafseo, grew 60% year-over-year to $21.3 million, supported by a 41% sequ